Geographic Distribution of Tigilanol Tiglate (EBC-46) Clinical Trial Sites: Where the Human Research Is Actually Happening
A look at where tigilanol tiglate human clinical trials have been conducted to date and what the geographic footprint tells us about EBC-46 translational research priorities.
When evaluating the human evidence base behind tigilanol tiglate — the isolated pharmaceutical compound derived from Fontainea picrosperma seed and developed by QBiotics Group — the geographic distribution of trial sites is informative. It tells readers which regulatory environments are currently engaged with the compound, where investigator expertise has clustered, and how broadly the safety and efficacy signal has been tested across populations.
The Australian centre of gravity
The bulk of early human work on tigilanol tiglate has been conducted in Australia, which is unsurprising given that QBiotics is an Australian company and the discovery program emerged from QIMR Berghofer in Brisbane. Phase I dose-finding and the early Phase II work in cutaneous and subcutaneous tumours have been concentrated at Australian sites — including major teaching hospitals in Queensland, New South Wales and Victoria — under TGA oversight. This concentration is typical of first-in-human and early-Phase II programs, where investigator continuity and proximity to the sponsor accelerate protocol amendments.
The Australian regulatory pathway has been the home environment for the compound and informed the manufacturing and clinical-quality standards we examined in our review of Phase III pivotal trial design considerations for tigilanol tiglate.
European expansion
As QBiotics has progressed tigilanol tiglate's development into squamous cell carcinoma of the head and neck (SCCHN), soft-tissue sarcoma and melanoma indications, European sites have been added. United Kingdom centres, primarily teaching hospitals with established Phase I/II oncology capacity, have participated. Sites in Germany and Italy have also been listed on public trial registries for specific indication-expansion studies. The European Medicines Agency (EMA) pathway runs in parallel with the U.S. and Australian programs, and adding European centres broadens the population represented in efficacy and safety data.
United States participation
U.S. trial activity has been added in selected centres with cutaneous oncology and head-and-neck expertise. The U.S. footprint remains smaller than the Australian one but is meaningful, particularly for the soft-tissue sarcoma program and the dog STT pivotal program that supported Stelfonta's veterinary FDA approval. Single-site U.S. studies have also been used for investigator-initiated work, including in tumour types not yet pursued in registration-quality trials.
Why geographic spread matters
There are three reasons the geographic footprint matters. First, regulatory exposure: each site brings the compound into contact with a different regulatory framework, which informs how the eventual registration dossier is assembled. Second, population diversity: tumour biology, comorbidity patterns and standard-of-care backgrounds vary across regions, and multi-region trials give a more generalisable picture of how the compound performs. Third, investigator network: building a multi-country investigator base reduces single-site bias and creates the infrastructure needed for confirmatory studies. The methodological design of those confirmatory studies is something we explored in detail when examining inclusion and exclusion criteria in tigilanol tiglate trials.
What the published record shows
The first peer-reviewed human safety and efficacy data — Panizza and colleagues' Phase I study in cutaneous and subcutaneous tumours — was published in 2019 with patients enrolled at Australian sites. Subsequent updates and expansion data have been presented at ASCO, ESMO and AACR meetings, with site lists indicating progressive geographic broadening. The ClinicalTrials.gov registry lists active and completed studies and is the most up-to-date public source for site lists, though primary investigators are not always disclosed at the site level.
What's missing: Asia and Latin America
As of mid-2026, large-scale Asian and Latin American trial participation in tigilanol tiglate development has been limited. There are practical reasons for this — registration pathway sequencing, local regulatory engagement timing, and access to existing oncology trial networks — but the absence is worth noting because tumour biology and standard-of-care differ in those regions, and broader regional participation would strengthen the generalisability of any eventual approval. The regulatory mechanics for some of those regions are something we have covered, including in our analyses of Japan's PMDA framework and South Korea's MFDS botanical framework.
Important framing for consumers
Everything above relates to pharmaceutical-grade tigilanol tiglate administered as an intralesional injection in oncology trials, not to oral blushwood berry extract dietary supplements. The supplement category — including products such as the 10:1 whole-seed extract sold by Blushwood Health — is governed by separate frameworks (DSHEA in the U.S., equivalents elsewhere) and does not require clinical trials. Consumers should not conflate the two when reading trial geography updates.
References
1. ClinicalTrials.gov — Tigilanol Tiglate Trial Registry, 2026.
3. QBiotics Group — Clinical Trials Programme, 2026.
4. European Medicines Agency — Human Medicines Regulatory, 2026.
Related articles
- ctDNA as a Pharmacodynamic Biomarker in Tigilanol Tiglate Trials
- Quality-of-Life Endpoints in Tigilanol Tiglate Trials
- Adverse Event Profile in Tigilanol Tiglate Phase 2 Trials
This article is informational and discusses pharmaceutical clinical research separately from the dietary supplement category. EBC-46 supplements are not intended to diagnose, treat, cure or prevent any disease.
